Exact Sciences Corp.’s Cologuard Plus received U.S. FDA pre-market approval as a non-invasive colorectal cancer home ...

Recordati SpA is shelling out $825 million up front for global rights to Enjaymo (sutimlimab), the only therapy approved for treating the rare disease cold agglutinin disease. In the deal with Sanofi ...

Biopharma financings continued to outperform over the first nine months of 2024, hitting $86.2 billion, a 75% increase from the $49.35 billion raised during the same period in 2023. September alone ...

Researchers in the U.K. have succeeded in reverse engineering the defective cryptic splicing that drives amyotrophic lateral ...

Dark genome miner Enara Bio Ltd. has closed a $32.5 million series B that will see the lead program targeting the first of a novel class of cancer antigens it has discovered through to the clinic.

Flagship Pioneering and Singapore’s Agency for Science, Technology and Research (A*STAR) are jointly committing up to SGD100 ...

The increasing knowledge on how protein tau is organized in live cells has shown that the protein forms nanometer-sized ...

Immune checkpoint inhibitors targeting the PD-1/PD-L1 pathway are widely used in cancer immunotherapy, but poor tissue ...

Researchers from Johns Hopkins University have filed for protection of their Optimal Target Identification via Modelling of Arrhythmogenesis technology – a method that builds a model of a patient’s ...

Med-tech fundraising saw strong growth in 2024, with companies raising $21.24 billion in the first three quarters, a 48% increase over the $14.36 billion raised during the same period in 2023. However ...

Biopharma money raised to-date and by month in 2023, including public, private and other financings.